Dr. Reddys Laboratories is currently trading at Rs. 2731.00, down by 120.40 points or 4.22% from its previous closing of Rs. 2851.40 on the BSE.
The scrip opened at Rs. 2800.00 and has touched a high and low of Rs. 2800.00 and Rs. 2727.00 respectively. So far 77953 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 3689.00 on 20-Jul-2016 and a 52 week low of Rs. 2727.00 on 09-Mar-2017.
Last one week high and low of the scrip stood at Rs. 2893.80 and Rs. 2727.00 respectively. The current market cap of the company is Rs. 45442.26 crore.
The promoters holding in the company stood at 26.79%, while Institutions and Non-Institutions held 44.46% and 12.17% respectively.
Dr. Reddy’s Laboratories’ formulation manufacturing facility at Duvvada, Visakhapatnam, has been audited by the US Food and Drug Administration (USFDA), and the audit has been completed on March 8, 2017. The company has been issued a Form 483 with 13 observations, which it is addressing.
Earlier, the company’s API manufacturing plant at Miryalaguda, had been audited by the USFDA and the audit had been completed on February 21, 2017. The company had been issued a Form 483 with three observations, which it was addressing.
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.